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Many studies have estimated national chronic disease costs, but
state-level estimates are limited. The Centers for Disease Control
and Prevention developed the Chronic Disease Cost Calculator
(CDCC), which estimates state-level costs for arthritis, asthma,
cancer, congestive heart failure, coronary heart disease, hyperten-
sion, stroke, other heart diseases, depression, and diabetes.
Methods
Using publicly available and restricted secondary data from mul-
tiple national data sets from 2004 through 2008, disease-attribut-
able annual per-person medical and absenteeism costs were estim-
ated. Total state medical and absenteeism costs were derived by
multiplying per person costs from regressions by the number of
people in the state treated for each disease. Medical costs were es-
timated for all payers and separately for Medicaid, Medicare, and
private  insurers.  Projected  medical  costs  for  all  payers  (2010
through 2020) were calculated using medical costs and projected
state population counts.
Results
Median state-specific medical  costs  ranged from $410 million
(asthma)  to  $1.8  billion  (diabetes);  median  absenteeism costs
ranged from $5 million (congestive heart failure) to $217 million
(arthritis).
Conclusion
CDCC provides methodologically rigorous chronic disease cost
estimates. These estimates highlight possible areas of cost savings
achievable through targeted prevention efforts or research into
new interventions and treatments.
Introduction
Chronic diseases lead to increased medical costs and productivity
losses (eg, time lost from work) (1–4). Costs attributable to chron-
ic disease are expected to continue to grow (5). Many studies have
estimated national chronic disease costs, but state-level estimates
are  limited.  The  Centers  for  Disease  Control  and  Prevention
(CDC) developed the Chronic Disease Cost Calculator (CDCC) in
response to state chronic disease programs’ requests for technical
assistance in estimating state-level chronic disease costs. The CD-
CC was created in partnership with the National Association of
Chronic Disease Directors, the Agency for Healthcare Research
and Quality (AHRQ), and the National Pharmaceutical Council
(6). In this article, we provide an overview of CDCC. Additional
details, including the software and technical appendix, are avail-
able at www.cdc.gov/chronicdisease/calculator/ (6).
The first version of the CDCC, released in 2009, estimated state-
level Medicaid costs for 6 chronic diseases (6). The second ver-
sion, released in 2013 and described in this article, provides (new
features in italics) state-level medical costs, absenteeism costs, and
10-year medical cost projections for arthritis, asthma, cancer, con-
gestive heart failure (CHF), coronary heart disease (CHD), hyper-
tension, stroke, other heart diseases, depression, and diabetes (Ta-
ble 1). Medical estimates are generated for the entire state popula-
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tion (all payers including the uninsured) and separately for those
covered by specific payers (Medicaid, Medicare, and private insur-
ance). For each state, payer, chronic disease, and subpopulation
selected, the CDCC generates a standardized report presenting the
number of people treated for the disease, annual payer and absent-
eeism costs attributable to the disease (per-person and total), and
10-year medical cost projections for all payers combined. These
estimates supplement other disease burden measures of chronic
disease impact (eg, prevalence) and may identify opportunities for
targeting prevention programs to reduce risk factors and chronic
diseases. CDCC users can also generate customized state-level
cost estimates for selected chronic diseases by modifying key in-
puts. For example, the financial impact of prevention programs
could be simulated by inputting treated population prevalence
from other sources. The purpose of this article is to demonstrate
the CDCC by providing an example across all states and all pay-
ers.
Methods
The CDCC calculates state-level chronic disease medical and ab-
senteeism costs using 4 components: 1) state-specific payer popu-
lations, 2) treated population prevalence, 3) per-person medical
and absenteeism costs, and 4) medical cost projections (7). The
costs are representative of the noninstitutionalized and nursing
home population.
Component 1: state-specific payer populations
Default state-specific payer populations (ie, number with health
care coverage through payer) were estimated for all payers com-
bined and by specific payer category. Payer populations were not
mutually exclusive (eg, persons dually eligible for Medicare and
Medicaid were in each payer population). Payer populations were
calculated by using the following data: 2008 US Census Bureau
for all payers combined, fiscal year 2008 Medicaid Statistical In-
formation Statistics for Medicaid, Kaiser Family Foundation 2008
Medicare Health and Prescription Drug Plan Tracker for Medi-
care, and 2008 Current Population Survey (CPS) for the privately
insured (8–12).
For each payer group, we estimated the proportion in each of the 6
unique age (18–44, 45–64, or ≥65 years) and sex groups. We in-
cluded children (ie, aged 0 to 17) for asthma and depression only
because these conditions are common among them. Age and sex
distribution for all payers and private payers were calculated us-
ing 2008 US Census Bureau and 2008 CPS data, respectively. We
estimated Medicaid and Medicare enrolment by age and sex using
2007 through 2009 CPS data. Unlike the CMS population counts,
CPS represents the noninstitutionalized population only. We de-
rived each age- and sex-specific state-level payer population by
multiplying state payer populations by the age- and sex-specific
proportions.
Component 2: treated population prevalence
Treated population prevalence (ie, percentage treated annually)
was estimated in 2 steps. In step 2A, we estimated treated preval-
ence for the noninstitutionalized population using data from the
2004–2008  Medical  Expenditure  Panel  Survey  (MEPS)  (13).
MEPS is a nationally representative survey of the civilian nonin-
stitutionalized population administered by AHRQ. Professional
coders transcribe self-reported MEPS condition data using the In-
ternational Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM). We defined each disease using codes
from the AHRQ Clinical Classification System or CDC defini-
tions (both based on ICD-9-CM codes) (Table 1) (14). Treated
prevalence was receipt of any medical care, including prescription
drugs, in the previous year.
For each payer population in the noninstitutionalized population,
we used separate logistic regressions to predict the probability of
having each disease (4 payers × 10 chronic conditions = 40 mod-
els). For each individual i in payer population p, we estimated the
probability of disease d:
Pr(Yipd = 1) = Λ(Ageip, Sexip, Regionip, Yearip)
These models controlled for survey year and survey participants’
age, sex, and region of residence (Northeast, South, Midwest, or
West). All regression models accounted for MEPS’ complex sur-
vey design. We identified significant age-by-sex-by-region inter-
actions (at α = .05) using stepwise regressions. We predicted the
nationally representative treated population prevalence for 2004
through 2008 from the final, survey-weighted logistic regressions
for each age, sex, and region combination (2A).
Because MEPS does not survey the noninstitutionalized popula-
tion, we adjusted estimates by the most recent (2004) National
Nursing Home Survey (NNHS) (nationally representative sample
of US nursing homes) so that costs include treatment received by
nursing home residents (step 2B) (15). CDCC does not include
other institutionalized and noncivilian populations. We defined
diseases using ICD-9-CM codes based on any condition diagnosis
(primary or secondary) at either time of admission or survey (Ta-
ble 1). For each payer (payment source in NNHS), age, and sex
group, we used a survey-weighted total of the number of people
with each disease and scaled the MEPS treated population preval-
ence  by  the  following  ratio:  number  with  disease  (MEPS  +
NNHS) / number with disease (MEPS).
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We calculated the number who were treated for each disease in
2008 by multiplying the estimated treatment population preval-
ence for each payer/age/sex/region group by the estimated num-
ber  in  the corresponding payer/age/sex/state  specific  category
from Component 1 (Table 2).
Component 3: medical and absenteeism costs
Medical Costs
“All payers” analysis contained all medical costs in the 2004–2008
MEPS (payments, not providers’ charges, by public and private in-
surers and out-of-pocket payments by treatment recipients or oth-
er noninsurance payers). Each payer’s analysis used only costs
paid by that payer.
For each payer, we estimated default chronic disease medical costs
using a 5-part  process.  In step 3A(i),  we estimated per-person
medical costs using a logistic regression model that predicted the
probability that a person incurred any medical costs and a general-
ized linear model with a gamma distribution and log link that es-
timated annual medical costs for those incurring such costs.
Hypertension and diabetes are risk factors for other chronic condi-
tions, and costs for these conditions were estimated in separate
models that did not control for these sequelae conditions; that is,
the hypertension and diabetes models did not control for CHF,
CHD, stroke, other heart diseases, and renal failure. Additionally,
the diabetes model did not adjust for hypertension and dyslip-
idemia. Therefore, the CDCC’s default estimates for hypertension
and diabetes include the costs of sequelae. We caution users that
summing costs across selected diseases that include hypertension
and diabetes will overestimate costs for all the selected diseases.
The CDCC provides estimates for diseases of the heart and total
cardiovascular disease but avoids double-counting of costs across
diseases using methods described below (step 3A[ii]).
In step 3A(ii), we calculated each disease’s attributable costs by
comparing predicted costs for people with each unique combina-
tion of diseases with predicted costs for people without that com-
bination of diseases, while holding all other characteristics con-
stant. For example, we calculated costs of treated cancer alone and
cancer  with  hypertension as  2  different  disease  combinations.
Then we divided the total costs attributable to the disease combin-
ations back to the constituent diseases (ie, share of all cancer with
hypertension costs that are attributable to cancer). In this combina-
tion of diseases, the greater share of the costs is apportioned to the
disease with the larger regression coefficient (16). We estimated
per-person medical costs for each disease and age/sex/region cat-
egory using the national model’s coefficients (step 3A[i]).
In step 3A(iii), we used 2004 NNHS (15) and National Health Ex-
penditure Accounts (17) data to adjust  the per-person medical
costs to account for treatment received by nursing home residents
while in a nursing home (7). Because public use data on nursing
home residents’ disease treatment costs outside a nursing home
were not available, we assumed these costs were the same as per-
person medical costs for the noninstitutionalized population.
In step 3A(iv), we used restricted-access MEPS data to generate
state-specific  cost  adjustments  for  the  30  largest  states  and  9
Census divisions for  the smallest  20 states  and the District  of
Columbia. Among respondents with any medical costs,  we re-
gressed medical costs (on a log scale) on state/census division and
adjustment variables (technical appendix) using a 1-part model.
We estimated state-specific estimates, we multiplied the per-per-
son costs from step 3A(iii) by the coefficients from step 3A(iv).
For example, if per-person costs from the national model 3A(iii)
were $1,000 and the state coefficient from 3A(iv) was 1.10, state-
specific per-person costs were $1,100 ($1,000 × 1.10).
In step 3A(v), we adjusted MEPS cost data to 2010 dollars using
the gross domestic product price deflator (18) and multiplied per-
person medical cost estimates in each age/sex category by the es-
timated number of people covered by each payer in each state
from component one.
Absenteeism Costs
We separately estimated workdays lost for working adults and im-
plied lost workdays for parents of children who lost schooldays.
We predicted annual workdays missed by working adults using a
negative  binomial  model.  The  dependent  variable  was  annual
workdays missed due to illness or injury. Independent variables
were identical to medical cost regressions, including use of altern-
ate models for hypertension and diabetes. Among children, we es-
timated annual number of school days missed due to illness or in-
jury using negative binomial models. We assumed that one work-
ing parent also misses work on the days that his or her child is ab-
sent from school. We calculated workdays missed per person at-
tributable to each disease using the same method as that used for
medical costs (16). We estimated the value of missed workdays
using age/sex-specific average daily earnings (not including fringe
benefits) from the 2009 CPS.
Component 4: medical cost projections
We calculated projected chronic disease medical costs for all pay-
ers combined through 2020 using default cost estimates and pro-
jected 2010 through 2020 US Census Bureau state  population
counts (9). For each state, we multiplied the treated population
prevalence (age-  and sex-specific;  component  2)  by projected
number of state residents in the corresponding category for each
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year (2010 through 2020). Then we summed these age- and sex-
specific estimates to project the total number treated for each dis-
ease by state and year. We multiplied the projected per-person cost
of each disease for people in each age/sex/state category (compon-
ent 3) by the number in the corresponding category that were es-
timated to be treated for that disease. We summed the projections
for each category to estimate total annual costs of care for each
disease. Finally, we adjusted the cost projections for the Congres-
sional Budget Office’s estimate of real growth in medical spend-
ing not attributable to population growth and aging (19). Projec-
tions do not include cost increases due to inflation. Projections as-
sume no changes in insurance coverage or technology (20) and
that all of changes in the medical costs are driven by medical cost
growth (19) and changes in population size and demographics.
The technical appendix contains additional details on the analysis
(12).
Results
Among the 10 specific conditions reported in the CDCC, median
state-specific medical costs ranged from $410 million for asthma
to $1.8 billion for diabetes; median absenteeism costs ranged from
$5 million for CHF to $217 million for arthritis (Table 3). Across
states and chronic conditions, Medicaid and Medicare medical
costs represented 29% (depression) to 57% (CHF) of overall state
medical costs.
Discussion
Public health officials often lack the resources to estimate the eco-
nomic burden of chronic diseases. The CDCC estimates medical
and absenteeism costs of chronic diseases without additional data
requirements. Decision makers can generate customized estimates
for local populations of interest using accurate local data for these
populations.
The CDCC’s default estimates may differ from other cost estim-
ates because of variation in data sources, settings, populations
studied, disease prevalence definitions, cost measurement, and
study methods. For example, the Behavioral Risk Factor Surveil-
lance System (BRFSS) prevalence definition is based on a life-
time disease history (21) whereas the CDCC population preval-
ence required treatment within the year. Thus, the CDCC likely
contains higher costs but fewer persons with disease. Combining
disease prevalence estimates from other sources with MEPS per-
person treatment costs could overestimate total costs. Therefore,
we recommend using CDCC’s treated disease prevalence estim-
ates.
CDCC estimates may differ from other chronic disease cost estim-
ates  reported  elsewhere.  There  is  substantial  heterogeneity  in
methods used to derive medical cost estimates, and the most ap-
propriate  approach to estimating disease costs  depends on the
users’ needs, available data sources, and cost definitions. Some
costs are based on summing of payments only for claims with dia-
gnosis codes for the disease of interest (2,3) or summing all med-
ical costs for persons with the disease (1). CDCC aims to minim-
ize duplicated costs by estimating costs for persons with the dis-
ease that are attributed to the disease. Different methods have been
used to attribute costs to diseases (22,23) to avoid double count-
ing of costs across diseases (16) and to adjust for potential con-
founders. CDCC estimates may also differ from claims-based ana-
lysis, especially because CDCC estimates were derived from mul-
tiple data sources based on data from different geographic units
(region, nation), and results from the statistical analysis are them-
selves estimates. MEPS underestimates total medical expenditures
because 1) it does not capture all medical care use and expendit-
ures, including nondurable goods (eg, over-the-counter medica-
tions) and health services administered in nonmedical settings
(24); and 2) comparison of MEPS with other medical use data
demonstrates that MEPS respondents underreport medical events,
which leads to underestimates of treated prevalence and use (25).
CDCC results are not comparable across states for at least 2 reas-
ons. First, they were derived from data from different levels of
geographic detail (eg, methods for the 30 largest states differed
from those for smaller states), and second, MEPS survey weights
are not designed to be representative of state populations. CDCC
does not estimate productivity losses through caregiving to adults
with chronic disease, impaired productivity while at work, prema-
ture mortality, and reductions in the quality of life.
CDCC’s medical cost projections reflect historical medical cost
growth and demographic changes but do not account for changes
from Patient Protection and Affordable Care Act implementation.
However, projections provide a useful baseline for gauging im-
pact of current and future policies and may inform budgetary al-
locations for chronic disease prevention and early detection invest-
ments.
The CDCC provides state-level estimates of the economic burden
of selected chronic diseases, because many policy decisions are
made at the state level. Estimates highlight possible areas of cost
savings achievable through targeted prevention efforts or research
into new interventions and treatments. This information is vital for
program decisions and resource allocations for chronic disease
prevention and disease management programs.
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Tables
Table 1. Chronic Disease Definitions, Clinical Classification System Codea and 3-Digit ICD-9-CM
Disease Code
Arthritis ICD-9-CM: 274, 354, 390, 391, 443, 446, 710–716, 719–721, 725–729
Asthma CCS: 128; ICD-9-CM: 493
Cancer CCS: 11–43, 45
Cardiovascular disease
Diseases of the heart
   Congestive heart failure ICD-9-CM: 428
   Coronary heart disease ICD-9-CM: 410–414
   Other heart diseasesb ICD-9-CM: 390–392, 393–398, 415–416, 420–427, 429
Hypertension ICD-9-CM: 401–405
Stroke ICD-9-CM: 430–434, 436–438
Depression ICD-9-CM: 296, 311
Diabetes ICD-9-CM: 250
Abbreviations: CCS, Clinical Classification System; ICD-9-CM, International Classification of Diseases, 9th revision, clinical modification.
a CCS codes collapse ICD-9-CM codes into a smaller number of clinically meaningful categories (14).
b Includes arrhythmias, bacterial endocarditis, cardiomyopathy, congenital cardiovascular defects, rheumatic fever/rheumatic heart disease, and valvu-
lar heart disease.
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Table 2. Example of Components of All Payer Medical Cost Estimates for Coronary Heart Disease in California
Item Component No. Estimate
Population 1 36,756,666
Percentage treated 2 3.1
Treated population 2 1,156,300
Cost per person, $ 3 6,800
Total cost, $, millions  — 7,857
Abbreviation: —, not applicable.
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Table 3. State Costs Attributable to Selected Chronic Diseases, in Millions, 2010 Dollars
Chronic Condition
Medical Costs Absenteeism Costs
Medicaid and Medicare’s Portion of State Costs,
% (Range)Median (Range)
Arthritis 1,623 (206–11,490) 217 (28–1,791) 34.5 (29.1–42.5)
Asthma 410 (55–3,182) 48 (6–383) 50.3 (33.6–72.7)
Cancer 1,973 (227–13,614) 116 (15–916) 37.1 (30.4–43.0)
Cardiovascular disease, total 4,302 (411–26,062) 201 (23–1,396) 42.2 (37.6–51.7)
Diseases of the heart 2,376 (211–14,313) 76 (8–487) 45.8 (41.3–54.0)
   Congestive heart failure 256 (18–1,702) 5 (0–42) 56.7 (47.4–72.4)
   Coronary heart disease 1,340 (18–7,988) 58 (6–383) 38.9 (33.9–45.5)
   Other heart diseases 765 (68–4,623) 13 (1–79) 55.5 (47.3–68.2)
Hypertension 1,624 (167–10,032) 78 (9–546) 35.4 (30.8–45.8)
Stroke 873 (86–5,959) 64 (7–451) 50.9 (41.6–67.4)
Depression 892 (120–6,728) 97 (13–861) 29.0 (23.1–37.9)
Diabetes 1,780 (212–12,095) 72 (9–544) 40.1 (32.9–50.1)
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